FY2029 Earnings Forecast for GALT Issued By HC Wainwright

Galectin Therapeutics Inc. (NASDAQ:GALT - Free Report) - Research analysts at HC Wainwright issued their FY2029 earnings per share estimates for shares of Galectin Therapeutics in a research note issued on Wednesday, April 2nd. HC Wainwright analyst E. Arce forecasts that the company will earn ($0.91) per share for the year. HC Wainwright currently has a "Neutral" rating on the stock. The consensus estimate for Galectin Therapeutics' current full-year earnings is ($0.73) per share.

Galectin Therapeutics (NASDAQ:GALT - Get Free Report) last announced its quarterly earnings results on Monday, March 31st. The company reported ($0.19) EPS for the quarter, missing analysts' consensus estimates of ($0.16) by ($0.03).

Separately, StockNews.com cut Galectin Therapeutics from a "hold" rating to a "sell" rating in a research report on Monday, December 30th.

Galectin Therapeutics Stock Performance

NASDAQ:GALT traded up $0.11 during mid-day trading on Friday, hitting $1.38. The stock had a trading volume of 56,205 shares, compared to its average volume of 321,401. Galectin Therapeutics has a twelve month low of $0.73 and a twelve month high of $4.27. The stock has a market cap of $87.25 million, a price-to-earnings ratio of -1.90 and a beta of 0.79. The company's 50 day simple moving average is $1.46 and its 200 day simple moving average is $1.90.

Hedge Funds Weigh In On Galectin Therapeutics

Large investors have recently modified their holdings of the stock. State Street Corp grew its stake in Galectin Therapeutics by 9.3% in the 3rd quarter. State Street Corp now owns 251,014 shares of the company's stock valued at $690,000 after buying an additional 21,399 shares during the last quarter. Kovitz Investment Group Partners LLC acquired a new position in shares of Galectin Therapeutics in the third quarter valued at approximately $117,000. Barclays PLC increased its stake in shares of Galectin Therapeutics by 309.0% during the third quarter. Barclays PLC now owns 28,587 shares of the company's stock worth $79,000 after purchasing an additional 21,598 shares during the period. Geode Capital Management LLC lifted its holdings in Galectin Therapeutics by 2.5% during the 3rd quarter. Geode Capital Management LLC now owns 862,542 shares of the company's stock worth $2,372,000 after purchasing an additional 20,817 shares during the last quarter. Finally, Soltis Investment Advisors LLC bought a new stake in Galectin Therapeutics in the 3rd quarter valued at $387,000. 11.68% of the stock is owned by institutional investors.

About Galectin Therapeutics

Galectin Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma.